KR20250037595A - 경부 근긴장이상증의 치료 방법 - Google Patents

경부 근긴장이상증의 치료 방법 Download PDF

Info

Publication number
KR20250037595A
KR20250037595A KR1020257007090A KR20257007090A KR20250037595A KR 20250037595 A KR20250037595 A KR 20250037595A KR 1020257007090 A KR1020257007090 A KR 1020257007090A KR 20257007090 A KR20257007090 A KR 20257007090A KR 20250037595 A KR20250037595 A KR 20250037595A
Authority
KR
South Korea
Prior art keywords
botulinum toxin
positively charged
gly gly
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257007090A
Other languages
English (en)
Korean (ko)
Inventor
커티스 엘. 루에그
제이콥 엠. 와프
Original Assignee
레반스 테라퓨틱스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레반스 테라퓨틱스, 아이엔씨. filed Critical 레반스 테라퓨틱스, 아이엔씨.
Publication of KR20250037595A publication Critical patent/KR20250037595A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020257007090A 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법 Pending KR20250037595A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762508324P 2017-05-18 2017-05-18
US62/508,324 2017-05-18
PCT/US2018/033397 WO2018213710A1 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia
KR1020197037005A KR102777928B1 (ko) 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037005A Division KR102777928B1 (ko) 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법

Publications (1)

Publication Number Publication Date
KR20250037595A true KR20250037595A (ko) 2025-03-17

Family

ID=64274745

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257007090A Pending KR20250037595A (ko) 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법
KR1020197037005A Active KR102777928B1 (ko) 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197037005A Active KR102777928B1 (ko) 2017-05-18 2018-05-18 경부 근긴장이상증의 치료 방법

Country Status (13)

Country Link
US (3) US20200179498A1 (enExample)
EP (1) EP3624819A4 (enExample)
JP (1) JP2020520917A (enExample)
KR (2) KR20250037595A (enExample)
CN (1) CN110996979A (enExample)
AU (2) AU2018270092B2 (enExample)
BR (1) BR112019024082A2 (enExample)
CA (1) CA3064070A1 (enExample)
CO (1) CO2019014212A2 (enExample)
MX (1) MX2019013716A (enExample)
PH (1) PH12019502578A1 (enExample)
RU (1) RU2019141383A (enExample)
WO (1) WO2018213710A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490986T3 (pl) * 2009-10-21 2019-03-29 Revance Therapeutics, Inc. Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP4228599A4 (en) * 2020-10-13 2025-03-12 ReVance Therapeutics, Inc. METHODS FOR TREATMENT OF CERVICAL DYSTONIA
AU2022223782A1 (en) * 2021-02-21 2023-09-21 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
ES2691498T3 (es) * 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
LT2379104T (lt) * 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) * 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
HRP20171483T1 (hr) * 2011-01-07 2017-12-01 Revance Therapeutics, Inc. Topikalni pripravak koji se sastoji od botulinskog toksina i boje
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
CA3003447A1 (en) 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
WO2019090257A1 (en) * 2017-11-03 2019-05-09 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
MX2020005785A (es) * 2017-12-04 2020-10-28 Revance Therapeutics Inc Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.
RU2741221C1 (ru) 2020-04-30 2021-01-22 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом

Also Published As

Publication number Publication date
US20200179498A1 (en) 2020-06-11
JP2020520917A (ja) 2020-07-16
KR20200006587A (ko) 2020-01-20
RU2019141383A (ru) 2021-06-18
KR102777928B1 (ko) 2025-03-10
RU2019141383A3 (enExample) 2022-01-19
US20250319168A1 (en) 2025-10-16
CA3064070A1 (en) 2018-11-22
AU2018270092B2 (en) 2025-04-17
BR112019024082A2 (pt) 2020-06-16
NZ759612A (en) 2024-01-26
US12257293B2 (en) 2025-03-25
US20220096610A1 (en) 2022-03-31
CO2019014212A2 (es) 2020-01-17
PH12019502578A1 (en) 2020-07-20
MX2019013716A (es) 2020-10-12
EP3624819A1 (en) 2020-03-25
CN110996979A (zh) 2020-04-10
EP3624819A4 (en) 2021-03-24
AU2018270092A1 (en) 2019-12-19
WO2018213710A1 (en) 2018-11-22
AU2025205532A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
JP6559849B2 (ja) 注射用ボツリヌス毒素製剤
US12257293B2 (en) Methods of treatment for cervical dystonia
JP5690785B2 (ja) 改良されたボツリヌス毒素組成物
EP2413947B1 (en) Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
US20240269246A1 (en) Methods for treating cervical dystonia
HK40020585A (en) Methods of treatment for cervical dystonia
WO2025059665A1 (en) Serial treatment with botulinum toxin for cervical dystonia
US20250268996A1 (en) Methods of and compositions for treatment of upper limb spasticity
HK1240854A1 (en) Injectable botulinum toxin formulations
HK1162925A (en) Injectable botulinum toxin formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250304

Application number text: 1020197037005

Filing date: 20191213

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250403

Comment text: Request for Examination of Application